Transmembrane Prolyl 4 Hydroxylase - Drugs In Development, 2021
Transmembrane Prolyl 4 Hydroxylase - Drugs In Development, 2021
SUMMARY
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron%li%and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 5 molecules. The molecules developed by companies in Pre-Registration, Phase III and Phase I stages are 1, 2 and 2 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
The latest report Transmembrane Prolyl 4 Hydroxylase - Drugs In Development, 2021, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron%li%and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 5 molecules. The molecules developed by companies in Pre-Registration, Phase III and Phase I stages are 1, 2 and 2 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
The latest report Transmembrane Prolyl 4 Hydroxylase - Drugs In Development, 2021, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
- The report reviews Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
FibroGen Inc
GlaxoSmithKline Plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDO-3055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enarodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0463518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
Featured News & Press Releases
Jun 25, 2021: Astellas receives positive CHMP opinion for EVRENZO (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease
Apr 06, 2021: FibroGen provides additional information on Roxadustat
Apr 06, 2021: FibroGen announces FDA Advisory Committee to review Roxadustat new drug application tentatively Scheduled
Mar 01, 2021: FibroGen provides regulatory update on Roxadustat
Dec 21, 2020: Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
Dec 18, 2020: Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
Dec 02, 2020: FibroGen to present safety and efficacy analyses from roxadustat global phase 3 program at American Society of Hematology Annual Meeting
Nov 27, 2020: Astellas receives approval of EVRENZO (roxadustat) in Japan for the treatment of anemia of chronic kidney disease in adult patients not on dialysis
Nov 19, 2020: AstraZeneca demonstrates data on roxadustat at ASH 2020
Oct 22, 2020: FibroGen presents late-breaker abstract results on associations between hemoglobin levels and cardiovascular outcomes in roxadustat-treated patients with anemia of chronic kidney disease (CKD)
Oct 20, 2020: AstraZeneca to present update on Roxadustat at ASN Kidney Week 2020 Reimagined
Oct 19, 2020: New Roxadustat data in anemia of chronic kidney disease to be released at ASN Kidney Week 2020 Reimagined
Oct 14, 2020: FibroGen to present new efficacy and safety analyses from Roxadustat global phase 3 program at American Society of Nephrology Kidney Week 2020 Reimagined
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
FibroGen Inc
GlaxoSmithKline Plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDO-3055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enarodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0463518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
Featured News & Press Releases
Jun 25, 2021: Astellas receives positive CHMP opinion for EVRENZO (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease
Apr 06, 2021: FibroGen provides additional information on Roxadustat
Apr 06, 2021: FibroGen announces FDA Advisory Committee to review Roxadustat new drug application tentatively Scheduled
Mar 01, 2021: FibroGen provides regulatory update on Roxadustat
Dec 21, 2020: Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
Dec 18, 2020: Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
Dec 02, 2020: FibroGen to present safety and efficacy analyses from roxadustat global phase 3 program at American Society of Hematology Annual Meeting
Nov 27, 2020: Astellas receives approval of EVRENZO (roxadustat) in Japan for the treatment of anemia of chronic kidney disease in adult patients not on dialysis
Nov 19, 2020: AstraZeneca demonstrates data on roxadustat at ASH 2020
Oct 22, 2020: FibroGen presents late-breaker abstract results on associations between hemoglobin levels and cardiovascular outcomes in roxadustat-treated patients with anemia of chronic kidney disease (CKD)
Oct 20, 2020: AstraZeneca to present update on Roxadustat at ASN Kidney Week 2020 Reimagined
Oct 19, 2020: New Roxadustat data in anemia of chronic kidney disease to be released at ASN Kidney Week 2020 Reimagined
Oct 14, 2020: FibroGen to present new efficacy and safety analyses from Roxadustat global phase 3 program at American Society of Nephrology Kidney Week 2020 Reimagined
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by FibroGen Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by FibroGen Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
